Children with Cancer UK

Last updated

Children with Cancer UK (formerly Children with Leukaemia) is a United Kingdom-based charity dedicated to raising money for research and providing care for children with cancer and their families. The aims of their research projects are to understand what causes children to get cancer and to develop improved treatments. [1] The charity also organises days out and parties for families affected by childhood cancer. [2]

Contents

Children with Cancer UK
FormerlyChildren with Leukaemia
Company typeCharitable organisation (England)
Founded12 February 1988
HeadquartersThird floor, 21-27 Lamb's Conduit Street, London WC1N 3NL
Key people
Phil Hall (Trustee)
Revenue14,332,347 pound sterling (2017)  OOjs UI icon edit-ltr-progressive.svg
Number of employees
37 (2017)  OOjs UI icon edit-ltr-progressive.svg
Website www.childrenwithcanceruk.org.uk

History

Children with Cancer UK was established in 1987 by Eddie and Marion O’Gorman and their family in memory of their son, Paul, who died from leukemia. [3] The initial aim was to raise £100,000 for research and support. The O’Gormans lost a second child, their daughter Jean, [4] to cancer shortly after their first fundraising event (The Paul O’Gorman Banquet and Ball). [5] Subsequently, Diana, Princess of Wales became involved in the charity, which she inaugurated in 1988. In January 2022, Phil Hall was appointed as a trustee of the charity. [6]

Fundraising

Since 1987, Children With Cancer UK has raised over £290 million, [7] [8] which is used to support research into the causes and treatment of cancer in children and clinical trials. The charity also funds research centres, such as the Northern Institute for Cancer Research. [9] and respite accommodation for affected families. In 2007, they provided funding for a new £40 million biomedical research lab at the UCL Cancer Institute, named after the deceased Paul O'Gorman. [10]

In the early 2000s, the charity co-funded elements of clinical trial that improved outcomes for children with leukaemia. The trial involved development of a test called the Minimal Residual Disease (MRD) test, which measures how much leukaemia remains after treatment and how likely it is that a child will relapse. [11] [12] In 2017 the charity funded into the development of precision medicine as treatment, which involves the genetic profiling of children with cancer and their tumours in order to personalise their treatment plans. [13]

Support

The charity was supported by a range of organisations in the UK including Mr Men Little Miss, who lent their characters to the vests worn the charity's London Marathon entrants. [14]

For his services to charity Eddie O’Gorman was appointed an OBE in 2009. [15] In November 2018, he was presented with the Pride of Britain 'Lifetime Achievement' award. [4]

In 2019 it became the sponsor of League One football club Sunderland AFC. During the same season, BETDAQ donated its front-of-shirt sponsorship to the charity for its teams Sunderland AFC and Charlton Athletic F.C. [16] [17]

Related Research Articles

<span class="mw-page-title-main">Leukemia</span> Blood cancers forming in the bone marrow

Leukemia is a group of blood cancers that usually begin in the bone marrow and result in high numbers of abnormal blood cells. These blood cells are not fully developed and are called blasts or leukemia cells. Symptoms may include bleeding and bruising, bone pain, fatigue, fever, and an increased risk of infections. These symptoms occur due to a lack of normal blood cells. Diagnosis is typically made by blood tests or bone marrow biopsy.

<span class="mw-page-title-main">Acute lymphoblastic leukemia</span> Blood cancer characterised by overproduction of lymphoblasts

Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid line of blood cells characterized by the development of large numbers of immature lymphocytes. Symptoms may include feeling tired, pale skin color, fever, easy bleeding or bruising, enlarged lymph nodes, or bone pain. As an acute leukemia, ALL progresses rapidly and is typically fatal within weeks or months if left untreated.

<span class="mw-page-title-main">Mitoxantrone</span> Chemical compound

Mitoxantrone is an anthracenedione antineoplastic agent.

<span class="mw-page-title-main">Dasatinib</span> Chemical compound

Dasatinib, sold under the brand name Sprycel among others, is a targeted therapy medication used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). Specifically it is used to treat cases that are Philadelphia chromosome-positive (Ph+). It is taken by mouth.

<span class="mw-page-title-main">Blood Cancer UK</span>

Blood Cancer UK, is a UK-based charity dedicated to funding research into all blood cancers including leukaemia, lymphoma and myeloma, as well as offering information and support to blood cancer patients.

<span class="mw-page-title-main">Inotuzumab ozogamicin</span> Chemical compound

Inotuzumab ozogamicin, sold under the brand name Besponsa, is an antibody-drug conjugate medication used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It is administered by intravenous infusion.

Minimal residual disease (MRD), also known as Molecular residual disease, is the name given to small numbers of cancer cells that remain in a person either during or after treatment when the patient is in remission. Sensitive molecular tests are either in development or available to test for MRD. These can measure minute levels of cancer cells in tissue samples, sometimes as low as one cancer cell in a million normal cells, either using DNA, RNA or proteins.

<span class="mw-page-title-main">Forodesine</span> Chemical compound

Forodesine is a transition-state analog inhibitor of purine nucleoside phosphorylase studied for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and for treatment of B-cell acute lymphocytic leukemia (B-ALL).

Blinatumomab, sold under the brand name Blincyto, and known informally as blina, is a biopharmaceutical medication used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It belongs to a class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells. Blinatumomab specifically targets the CD19 antigen present on B cells. In December 2014, it was approved by the US Food and Drug Administration under the accelerated approval program; marketing authorization depended on the outcome of clinical trials that were ongoing at the time of approval. Blinatumomab is given via intravenous infusion.

<span class="mw-page-title-main">Donald Pinkel</span> American physician (1926–2022)

Donald Paul Pinkel was an American physician who specialized in pediatric hematology and oncology. Pinkel made contributions to cures for several forms of childhood cancer, including leukemia.

The Simon Flavell Leukaemia Research Laboratory is based at Southampton General Hospital and named after ten-year-old Simon Flavell who died in 1990 from an aggressive form of T-cell acute lymphoblastic leukemia (ALL). The laboratory specialises in researching and developing antibody type treatments for adults and children with currently incurable types of leukaemia.

Moxetumomab pasudotox, sold under the brand name Lumoxiti, is an anti-CD22 immunotoxin medication for the treatment of adults with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Moxetumomab pasudotox is a CD22-directed cytotoxin and is the first of this type of treatment for adults with HCL. The drug consists of the binding fragment (Fv) of an anti-CD22 antibody fused to a toxin called PE38. This toxin is a 38 kDa fragment of Pseudomonas exotoxin A.

<span class="mw-page-title-main">Neuroblastoma Children's Cancer Alliance UK</span>

The Neuroblastoma Children's Cancer Alliance UK, commonly referred to as NCCA UK, is a UK charity that helps children and families affected by neuroblastoma, a type of childhood cancer. The charity helps families by helping them to access and fundraise for their child's treatment abroad when no treatment is available in the UK, offering support and funding research into the condition.

<span class="mw-page-title-main">Children's Cancer Institute</span>

Children's Cancer Institute is an Australian medical research institute wholly dedicated to the prevention and treatment of childhood cancer. Established in 1976, the Institute is affililiated with both the University of New South Wales and Sydney Children's Hospital and is located in Randwick, Sydney, New South Wales.

Tisagenlecleucel, sold under the brand name Kymriah, is a CAR T cells medication for the treatment of B-cell acute lymphoblastic leukemia (ALL) which uses the body's own T cells to fight cancer.

<span class="mw-page-title-main">Children's Cancer Foundation (Australia)</span>

The Children's Cancer Foundation is a registered Australian charity that supports children with cancer and their families.

Christine J. Harrison is a Professor of Childhood Cancer Cytogenetics at Newcastle University. She works on acute leukemia and used cytogenetics to optimise treatment protocols.

<span class="mw-page-title-main">Nirali N. Shah</span> American physician-scientist and pediatric hematologist-oncologist

Nirali N. Shah is an American physician-scientist and pediatric hematologist-oncologist, serving as head of the hematologic malignancies section of the pediatric oncology branch at the National Cancer Institute. She researches the translation of immunotherapeutic approaches to treat high-risk hematologic malignancies in children, adolescents and young adults.

<span class="mw-page-title-main">Mary V. Relling</span> American pharmacogeneticist

Mary Violet Relling is an American pharmacogeneticist. Relling's research focuses on pharmacokinetics and pharmacodynamics in children and how genome variability influences a child's response to cancer chemotherapy.

<span class="mw-page-title-main">Adele Fielding</span> British physician

Adele Kay Fielding is a British physician-scientist who is a Professor of Haematology at University College London. Fielding was President of the British Society for Haematology from 2020 until 2022.

References

  1. "Charity overview". Charity Commission for England and Wales. Retrieved 12 January 2019.
  2. Newton-Browne, Lily (28 April 2019). "Charity treats children with cancer to day out at Weston Grand Pier". Weston Mercury. Retrieved 15 October 2021.
  3. "Sunshine fun for marathon runner appealing for support in Thame". The Bucks Herald. Aylesbury, England: JPIMedia. 31 January 2018. Retrieved 12 January 2019.
  4. 1 2 McNally, Siobhan (4 November 2018). "Pride of Britain winner Eddie O'Gorman raised £230m to fight cancer - his story". Mirror Online. London: MGN > Trinity Mirror Group. Retrieved 6 November 2018.
  5. Stevens, Richard G. "Bugs" (17 April 2018). "Light at night can disrupt circadian rhythms in children – are there long-term risks?". The Conversation. Boston. Retrieved 12 January 2019.
  6. "Our Founder and Trustees | Children with Cancer UK". Children with Cancer. Retrieved 13 January 2022.
  7. Norris, Phil (11 April 2018). "Mum running London Marathon after daughter got cancer". gloucestershirelive. Retrieved 12 April 2018.
  8. "Our impact and success | Children with Cancer UK". Children with Cancer. Retrieved 13 January 2022.
  9. "Paul died, but his legacy is hope". The Northern Echo. 25 February 2005.
  10. "Cancer research and the transformational power of philanthropy". 2 February 2018. Archived from the original on 30 April 2021. Retrieved 12 April 2018.
  11. O’Connor, David; Enshaei, Amir; Bartram, Jack; Hancock, Jeremy; Harrison, Christine J.; Hough, Rachael; Samarasinghe, Sujith; Schwab, Claire; Vora, Ajay; Wade, Rachel; Moppett, John (1 January 2018). "Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia". Journal of Clinical Oncology. 36 (1): 34–43. doi:10.1200/JCO.2017.74.0449. ISSN   0732-183X. PMC   5756322 . PMID   29131699.
  12. Furness, Caroline L.; Kirkwood, Amy; Rowntree, Clare; Vora, Ajay; Mitchell, Chris; Samarasinghe, Sujith; Goulden, Nicholas; Moorman, Anthony; Hough, Rachael (2019). "Early morphological response is significantly associated with, but does not accurately predict, relapse in teenagers and young adults aged 10–24 years with acute lymphoblastic leukaemia (ALL): results from UKALL2003". British Journal of Haematology. 184 (4): 663–666. doi: 10.1111/bjh.15150 . ISSN   1365-2141. PMID   29468646. S2CID   207087328.
  13. George, Sally L.; Izquierdo, Elisa; Campbell, James; Koutroumanidou, Eleni; Proszek, Paula; Jamal, Sabri; Hughes, Deborah; Yuan, Lina; Marshall, Lynley V.; Carceller, Fernando; Chisholm, Julia C. (November 2019). "A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations". European Journal of Cancer. 121: 224–235. doi:10.1016/j.ejca.2019.07.027. ISSN   0959-8049. PMC   6839402 . PMID   31543384.
  14. "Children with Cancer UK launches The Mr. Men Little Miss Virtual Run | UK Fundraising". fundraising.co.uk. 23 February 2017. Retrieved 12 April 2018.
  15. "New Year honours list: OBEs". The Guardian. 31 December 2009.
  16. Johns, Craig (22 May 2019). "Amazing gesture from Betdaq will see children's cancer charity as Sunderland's shirt sponsor". ChronicleLive. Retrieved 15 October 2021.
  17. ITRM. "Shirt sponsorship donated to Children with Cancer UK for 2019/20 season". www.cafc.co.uk. Retrieved 15 October 2021.